LGL Partners’s Cogent Biosciences COGT Stock Holding History

LGL Partners’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,500	Closed	-$208K	–	55
2025 Q3	$208K	Hold	14,500	–	–	0.09%	55
2025 Q2	$157K	Hold	14,500	–	–	0.07%	56
2025 Q1	$86.9K	Hold	14,500	–	–	0.04%	53
2024 Q4	$113K	Hold	14,500	–	–	0.02%	122
2024 Q3	$157K	Hold	14,500	–	–	0.02%	119
2024 Q2	$122K	Hold	14,500	–	–	0.02%	112
2024 Q1	$97.4K	Hold	14,500	–	–	0.02%	102
2023 Q4	$85.3K	Hold	14,500	–	–	0.01%	98
2023 Q3	$141K	Hold	14,500	–	–	0.02%	90
2023 Q2	$172K	Hold	14,500	–	–	0.03%	95
2023 Q1	$156K	Hold	14,500	–	–	0.03%	94
2022 Q4	$168K	Hold	14,500	–	–	0.03%	89
2022 Q3	$216K	Hold	14,500	–	–	0.05%	128
2022 Q2	$131K	Buy	+14,500	New	+$99K	0.02%	93

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LGL Partners's COGT Position: Q4 2025 in Review

LGL Partners sold out of Cogent Biosciences (COGT) in Q4 2025, closing a stake of 14,500 shares — an estimated $208K sold.

LGL Partners first reported a position in COGT in Q2 2022 and held it in 14 quarters. The position peaked at $216K in Q3 2022. 267 funds tracked by Wall St. Rank hold COGT as of Q4 2025.

LGL Partners reported no remaining Cogent Biosciences position as of Q4 2025 after selling out during the quarter.
LGL Partners sold 14,500 Cogent Biosciences shares in Q4 2025, an estimated $208K.
LGL Partners first reported a position in Cogent Biosciences in Q2 2022 and held it in 14 quarters.
LGL Partners's Cogent Biosciences position peaked at $216K in Q3 2022.
267 funds tracked by Wall St. Rank held Cogent Biosciences as of Q4 2025.

Based on LGL Partners's 13F filing for Q4 2025, filed 9 Feb 2026.